ADORA2A and Parkinson disease: The recent approval of the A2AR antagonist Nourianz® (istradefylline) by the U.S. Food and Drug Administration (FDA) as an add-on treatment to levodopa in Parkinson’s disease (PD) with “OFF” episodes in 2019 [28] have demonstrated its noted safety profile and clinical utility.